Short Interest in Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Declines By 40.4%

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) was the target of a significant decline in short interest in June. As of June 30th, there was short interest totaling 155,235 shares, a decline of 40.4% from the June 15th total of 260,360 shares. Currently, 5.0% of the company’s shares are short sold. Based on an average daily volume of 252,050 shares, the days-to-cover ratio is currently 0.6 days.

Valion Bio, Inc. Common Stock Stock Up 3.4%

NASDAQ:VBIO traded up $0.02 during trading hours on Friday, reaching $0.51. The company had a trading volume of 431,617 shares, compared to its average volume of 227,871. Valion Bio, Inc. Common Stock has a twelve month low of $0.40 and a twelve month high of $5.60. The company has a quick ratio of 3.02, a current ratio of 3.31 and a debt-to-equity ratio of 0.62. The firm has a market cap of $1.62 million, a price-to-earnings ratio of -0.08 and a beta of 1.82. The business’s 50-day simple moving average is $0.67 and its two-hundred day simple moving average is $0.92.

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($2.23) earnings per share for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a research note on Monday, April 20th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Valion Bio, Inc. Common Stock Company Profile

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.